Ab­b­Vie op­tions in­te­grin-based com­pounds from Mor­phic, paving way for po­ten­tial fi­bro­sis treat­ments

Al­most two years af­ter first ink­ing a deal with Ab­b­Vie worth $100 mil­lion up­front, Mor­phic Ther­a­peu­tic re­ceived an­oth­er bit of good news from the phar­ma gi­ant.

The biotech an­nounced Tues­day morn­ing that Ab­b­Vie has ex­er­cised a li­cens­ing op­tion as part of that 2018 agree­ment, giv­ing the phar­ma ex­clu­sive rights to two in­te­grin in­hibitors pro­grams for id­io­path­ic pul­monary fi­bro­sis and oth­er fi­bro­sis-re­lat­ed dis­eases. Mor­phic will re­ceive a $20 mil­lion li­cens­ing fee with po­ten­tial fu­ture mile­stone pay­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.